Advanced dermal filler with 24mg/ml medical-grade hyaluronic acid and 0.3% lidocaine. Features Hy-BRID™ cross-linking technology for 6-month duration with optimal viscoelasticity (G’ 250-350Pa). ISO 13485 certified formulation demonstrates 98.7% purity in clinical trials, FDA-cleared for nasolabial folds correction.

CLINICAL ADVANTAGES

HY-BRID™ TECHNOLOGY

• Patented particle size distribution (500-800μm)
• Optimized cross-linking density (4-6%)
• Rheology-tested cohesivity (tanδ 0.25-0.35)

CLINICAL PACKAGE

▸ 1mL prefilled syringe
▸ 2-25°C thermal stability
▸ Batch-tracked sterile packaging

PROTOCOL FOR PRACTITIONERS

1. Subcutaneous injection (0.02-0.1mL/site)
2. Max 2.0mL per treatment session
3. 4-6 week treatment intervals
4. Aspiration test mandatory
5. Post-treatment cooling recommended

*KGMP-certified manufacturing. Results may vary ±23% based on individual metabolism and injection technique. Not for periorbital use. Contraindicated in patients with autoimmune disorders. Post-market surveillance data shows 0.09% adverse event rate (2023 report).